What is the revenue and EPS growth rate for Caris Life Sciences year over year?

What is Caris Life Sciences's latest dividend and current dividend yield?

What is Caris Life Sciences's gross profit margin?

What were the key takeaways from Caris Life Sciences’s earnings call?

Did Caris Life Sciences beat or miss consensus estimates last quarter?

What guidance did Caris Life Sciences's management provide for the next earnings period?

What does Caris Life Sciences do and what are its main business segments?

What were the key takeaways from Caris Life Sciences's earnings call?

- **Revenue Supercharge**: 113% YoY growth ($720M+ 2025) driven by 121% mol prof services, 18% pharma R&D.
- **AI-Powered Margins**: 68% gross margin (Q3 2025) vs 43.7% 2024, ASPs up 15% tissue, 18% blood.
- **Pipeline Breakthroughs**: MRD 96% sensitivity, whole genome early detection enrolling 16,000+ subjects.
- **Cash Flow Dominance**: $55M free cash flow,3Q25, balance sheet $760M.
- **2025 Outlook**: 21-22% clinical growth, 68%+ gross margin target.
- **Strategic Wins**: 80%+ MRD accuracy, 18% blood ASP growth.
- **Pipeline Momentum**: Early detection, MRD, pharma R&D expansion.
- **Execution Excellence**: 68% gross margin, 15% ASP expansion.
- **Future Growth**: 2025+ pipeline with whole genome sequencing, MRD commercialization.

**【CEO Summary Section】**
- CEO highlighted Q3 2025 revenue growth of 113% YoY, driven by molecular profiling services ($207.6M, +121% YoY) and pharma R&D ($9.2M, +18.3% YoY). 
- Emphasized AI-driven early detection pipeline progress, with ACHIEVE-1 whole genome study enrolling 16,000 subjects and ACHIEVE-2 targeting 25,000 high-risk individuals.
- Gross margin improved to 68% (Q3 2025) from 43.7% (Q2 2025), with ASPs rising to $3,600+ for tissue and $2,377 for blood.

**【CFO Financial Commentary】**
- GAAP net income $24.3M, non-GAAP EPS $1.08 vs. $0.85 prior guidance.
- Free cash flow $55.3M, up 125% YoY, with balance sheet strength at $760M.
- 2025 guidance updated to $720-730M revenue (+75% YoY), 21-22% clinical case volume growth.
- 2025 gross margin target 68%+ vs. 43.7% 2024, driven by ASP expansion and lab efficiency gains.

**【Q&A Highlights】**
- MRD pipeline progress: Colorectal cancer MRD solution showing 96.3% sensitivity vs. 80%+ recurrence prediction accuracy.
- Blood ASPs up 18% Q3, tissue ASPs up 15% YoY, with 2025 ASP guidance $3,600+ tissue, $2,377 blood.
- Early detection pipeline: Whole genome sequencing for early cancer detection in development, with 18,600 subjects enrolled in ACHIEVE-1.
- Pharma R&D services up 18.3% YoY, with multi-year partnerships in pipeline.
- 2025 gross margin target 68%+, up from 43.7% 2024

Caris Life Sciences, Inc. (CAI) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

CAI

CAI fundamentals

You can ask Aime